Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

261. A New Era for Anticoagulation in Atrial Fibrillation. Full Text available with Trip Pro

A New Era for Anticoagulation in Atrial Fibrillation. 21870977 2011 09 27 2015 11 19 1533-4406 365 11 2011 Sep 15 The New England journal of medicine N. Engl. J. Med. A new era for anticoagulation in atrial fibrillation. 1052-4 10.1056/NEJMe1109748 Mega Jessica L JL eng Comment Editorial 2011 08 27 United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Benzimidazoles 0 Morpholines 0 Pyrazoles 0 Pyridones 0 Thiophenes 11P2JDE17B beta-Alanine 3Z9Y7UWC1J apixaban 5Q7ZVV76EI Warfarin (...) 9NDF7JZ4M3 Rivaroxaban I0VM4M70GC Dabigatran AIM IM N Engl J Med. 2012 Jan 5;366(1):88-9; author reply 89-90 22216850 N Engl J Med. 2011 Sep 15;365(11):981-92 21870978 N Engl J Med. 2011 Sep 8;365(10):883-91 21830957 N Engl J Med. 2009 Sep 17;361(12):1139-51 19717844 Anticoagulants therapeutic use Atrial Fibrillation drug therapy Benzimidazoles therapeutic use Dabigatran Humans Morpholines therapeutic use Pyrazoles therapeutic use Pyridones therapeutic use Rivaroxaban Stroke prevention & control

2011 NEJM

262. New Options in Anticoagulation for Atrial Fibrillation. Full Text available with Trip Pro

New Options in Anticoagulation for Atrial Fibrillation. 21830960 2011 09 16 2016 10 25 1533-4406 365 10 2011 Sep 08 The New England journal of medicine N. Engl. J. Med. New options in anticoagulation for atrial fibrillation. 952-3 10.1056/NEJMe1107516 del Zoppo Gregory J GJ Eliasziw Misha M eng R01 NS053716 NS NINDS NIH HHS United States R37 NS038710 NS NINDS NIH HHS United States Comment Editorial 2011 08 10 United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Benzimidazoles 0 (...) Morpholines 0 Thiophenes 11P2JDE17B beta-Alanine 5Q7ZVV76EI Warfarin 9NDF7JZ4M3 Rivaroxaban I0VM4M70GC Dabigatran AIM IM N Engl J Med. 2011 Sep 8;365(10):883-91 21830957 N Engl J Med. 2009 Sep 17;361(12):1139-51 19717844 Anticoagulants therapeutic use Atrial Fibrillation drug therapy Benzimidazoles therapeutic use Dabigatran Humans Intention to Treat Analysis Intracranial Hemorrhages chemically induced Morpholines therapeutic use Rivaroxaban Thiophenes therapeutic use Warfarin therapeutic use beta-Alanine

2011 NEJM

263. Low Dose Vitamin K Supplementation and Anticoagulation Control

Low Dose Vitamin K Supplementation and Anticoagulation Control Low Dose Vitamin K Supplementation and Anticoagulation Control – Clinical Correlations Search Low Dose Vitamin K Supplementation and Anticoagulation Control July 21, 2011 7 min read By Joanna Becker Faculty Peer Reviewed Patients who are placed on long-term warfarin ( Coumadin ) therapy are sent home with a lengthy list of restrictions to minimize variations in warfarin efficacy. The agents that can alter warfarin levels can (...) be divided into 2 categories: (1) those that interact with cytochrome P450, which metabolizes warfarin and (2) those that alter phytonadione (vitamin K) levels. The majority of inter- and intra-individual warfarin dose variability is attributable to the agents in category 1 above, which include everything from antibiotics, antihistamines, and barbiturates to alcohol and antacids. However, once one controls for these variables, oral intake of vitamin K persists as an integral factor in anticoagulation

2011 Clinical Correlations

264. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Full Text available with Trip Pro

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial.The RE-LY trial randomized 18

2011 EvidenceUpdates Controlled trial quality: uncertain

265. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes

Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

266. Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran. Full Text available with Trip Pro

Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran. 21488759 2011 06 01 2015 11 19 1533-4406 364 19 2011 May 12 The New England journal of medicine N. Engl. J. Med. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran. 1788-90 10.1056/NEJMp1103050 Beasley B Nhi BN Division of Cardiovascular and Renal Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA (...) . Unger Ellis F EF Temple Robert R eng Journal Article 2011 04 13 United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Benzimidazoles 11P2JDE17B beta-Alanine 5Q7ZVV76EI Warfarin I0VM4M70GC Dabigatran AIM IM Anticoagulants administration & dosage adverse effects Atrial Fibrillation drug therapy Benzimidazoles administration & dosage adverse effects Dabigatran Drug Approval Embolism prevention & control Hemorrhage chemically induced Humans Stroke prevention & control Therapeutic Equivalency

2011 NEJM

267. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort Full Text available with Trip Pro

Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort The risk of stroke in patients with atrial fibrillation (AF) is not homogeneous, and various clinical risk factors have informed the development of stroke risk stratification schemes (RSS). Among anticoagulated cohorts, the emphasis should be on the identification of patients who remain at high risk for stroke (...) despite anticoagulation.We investigated predictors of thromboembolism (TE) risk in an anticoagulated AF clinical trial cohort (n = 7329 subjects) and tested the predictive value of contemporary RSS in this cohort: CHADS₂, Framingham, NICE 2006, American College of Cardiology/American Heart Association/European Society of Cardiology 2006, the 8th American College of Chest Physicians guidelines and the CHA₂DS₂-VASc schemes.On multivariate analysis, significant predictors of TE were stroke/TIA (hazard

2011 EvidenceUpdates

268. Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs Full Text available with Trip Pro

Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs The purpose of this study was to investigate predictors of bleeding in a cohort of anticoagulated patients and to evaluate the predictive value of several bleeding risk stratification schemas.The risk of bleeding during antithrombotic therapy (...) in patients with atrial fibrillation (AF) is not homogeneous, and several clinical risk factors have been incorporated into clinical bleeding risk stratification schemas. Current risk stratification schemas for bleeding during anticoagulation therapy have been based on complex scoring systems that are difficult to apply in clinical practice, and few have been derived and validated in AF cohorts.We investigated predictors of bleeding in a cohort of 7,329 patients with AF participating in the SPORTIF

2011 EvidenceUpdates Controlled trial quality: uncertain

269. [Biology of haemostasis disorders: lupus anticoagulant detection]

[Biology of haemostasis disorders: lupus anticoagulant detection] Biologie des anomalies de l'hémostase : détection d'un anticoagulant de type lupique [Biology of haemostasis disorders: lupus anticoagulant detection] Biologie des anomalies de l'hémostase : détection d'un anticoagulant de type lupique [Biology of haemostasis disorders: lupus anticoagulant detection] Haute Autorité de Santé Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Haute Autorité de Santé. Biologie des anomalies de l'hémostase : détection d'un anticoagulant de type lupique. [Biology of haemostasis disorders: lupus anticoagulant detection] . Paris: Haute Autorité de Santé (HAS). 2011 Authors' objectives The National Salaried Workers' Health Insurance Fund (CNAMTS) asked HAS to assess the value of the different laboratory tests for haemostasis abnormalities

2011 Health Technology Assessment (HTA) Database.

270. Oral anticoagulation with warfarin - 4th edition

Oral anticoagulation with warfarin - 4th edition Guidelines on oral anticoagulation with warfarin – fourth edition - Keeling - 2011 - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. guideline Free Access Guidelines on oral anticoagulation with warfarin – fourth edition (...) can be found at . The objective of this guideline is to provide healthcare professionals with clear guidance on the indications for and management of patients on warfarin. This guideline replaces the previous BCSH guidelines on oral anticoagulants ( ; ). 1. Indications for warfarin and recommended target international normalized ratio (INR) This guideline refers to target INRs rather than target ranges, although the target range is generally taken to be within 0·5 of the target, i.e. a target INR

2011 British Committee for Standards in Haematology

271. The dental patient on oral anticoagulant medication: a literature review

The dental patient on oral anticoagulant medication: a literature review The dental patient on oral anticoagulant medication: a literature review The dental patient on oral anticoagulant medication: a literature review Kosyfaki P, Att W, Strub JR CRD summary This review concluded that different anticoagulation strategies were associated with varying complications, during dental treatment. There was insufficient evidence to determine the safest successful dental treatment. The authors (...) ’ conclusions were suitably cautious and appropriate, reflecting the limited evidence available. Authors' objectives To evaluate the relationship between anticoagulant medication and dental treatment. Searching PubMed was searched for relevant English-language publications from 1988 to October 2010. Search terms were reported. High-yield journals (not specified) and relevant bibliographies were manually screened. Study selection Eligible for inclusion were studies assessing the relationship between oral

2011 DARE.

272. A Synthesis of the Evidence: Safe and Effective Anticoagulation in the Outpatient Setting

A Synthesis of the Evidence: Safe and Effective Anticoagulation in the Outpatient Setting Management Briefs Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs Health Services Research & Development Management Briefs Management eBriefs: Provide VA senior managers with results from VA Health Services Research in a concise and timely manner. , April 2019, Issue 152 , March 2019, Issue 151

2011 Veterans Affairs - R&D

273. Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement (Abstract)

Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement Self-management improves oral anticoagulation control. Here we provide data of a preplanned interim analysis of very low-dose early self-controlled anticoagulation.In a prospective, randomized, multicenter trial, 1,137 patients performed low-dose international normalized ratio (INR) self-management with a target INR range of 1.8. to 2.8 for aortic valve replacement

2011 EvidenceUpdates Controlled trial quality: uncertain

274. Safe and Effective Anticoagulation in the Outpatient Setting

Safe and Effective Anticoagulation in the Outpatient Setting Evidence-based Synthesis Program Safe and Effective Anticoagulation in the Outpatient Setting: A Systematic Review of the Evidence Department of Veterans Affairs Health Services Research & Development Service February 2011 Investigators: Principal Investigators: Hanna E. Bloomfield, MD, MPH Brent C. Taylor, PhD, MPH Co-Investigators: Ange Krause, MD Preetham Reddy, MD Research Associates: Nancy Greer, PhD Roderick MacDonald, MS (...) Indulis Rutks, BA Prepared for: Department of Veterans Affairs Veterans Health Administration Health Services Research & Development Service Washington, DC 20420 Prepared by: VA Evidence-based Synthesis Program (ESP) Center Center for Chronic Disease Outcomes Research Minneapolis VA Medical Center Minneapolis, MN Timothy J. Wilt, MD, MPH, Directori Safe and Effective Anticoagulation in the Outpatient Setting Evidence-based Synthesis Program This report is based on research conducted by the Evidence

2011 Veterans Affairs Evidence-based Synthesis Program Reports

275. Interventions other than anticoagulants and systemic antibiotics for prevention of central venous catheter-related infections in children with cancer. (Abstract)

Interventions other than anticoagulants and systemic antibiotics for prevention of central venous catheter-related infections in children with cancer. Use of central venous catheters (CVC) in treatment of children with cancer is associated with infective complications. Current evidence-based guidelines to prevent catheter-related infections are mainly relevant to the adult population. They are not cancer (especially not childhood cancer) specific. Two existing Cochrane reviews have looked (...) at prophylactic antibiotics and anticoagulants to prevent CVC-related infections.The primary objective was to find which interventions, if any, were effective in preventing CVC-related infections in children with cancer. Further objectives were to examine the effectiveness of each intervention in the following subgroups: implanted versus external catheters, haematological versus non-haematological malignancies, and in those receiving haematopoietic stem cell transplants (HSCT) versus no HSCT.We searched

2010 Cochrane

276. Drug and dietary interactions of the new and emerging oral anticoagulants (Abstract)

Drug and dietary interactions of the new and emerging oral anticoagulants Oral warfarin is associated with extensive food and drug interactions, and there is a need to consider such interactions with the new oral anticoagulants (OACs) dabigatran etexilate, rivaroxaban and apixaban. A literature survey was conducted using PubMed, EMBASE and recent abstracts from thrombosis meetings to identify publications related to food, drug and dietary supplement interaction studies with dabigatran etexilate

2010 EvidenceUpdates

277. Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy. Full Text available with Trip Pro

Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy. Thromboembolic complications are much higher in pregnancy due to procoagulant changes. Heparin does not cross the placenta and the use of unfractionated heparin (UFH) is the current established practice in prophylaxis and treatment for thromboembolism in pregnancy.To compare the effectiveness of anticoagulant therapies for the treatment of deep vein thrombosis in pregnancy. The anticoagulant drugs included are UFH, low molecular (...) did not identify any eligible studies for inclusion in the review.We identified three potential studies; after assessing eligibility, we excluded all three as they did not meet the prespecified inclusion criteria. One study compared LMWH and UFH in pregnant women with previous thromboembolic events and, for most of these women, anticoagulants were used as thromboprophylaxis. There were only three women who had a thromboembolic event during the current pregnancy and it was unclear whether

2010 Cochrane

278. Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures

Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted (...) anticoagulant therapy for simple oral surgical procedures Ralph Rosenblum Jr. DDS, MHA . Overview Systematic Review Conclusion Patients taking oral anticoagulant therapy [OAT] did not experience a higher risk of post-operative bleeding compared to patients not on OAT or OAT patients who discontinue therapy following simple oral surgical procedures. Critical Summary Assessment The findings suggest that it is not necessary to discontinue OAT for simple oral surgical procedures. Evidence Quality Rating Good

2010 ADA Center for Evidence-Based Dentistry

279. Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures

Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted (...) anticoagulant therapy for simple oral surgical procedures Ralph Rosenblum Jr. DDS, MHA . Overview Systematic Review Conclusion Patients taking oral anticoagulant therapy [OAT] did not experience a higher risk of post-operative bleeding compared to patients not on OAT or OAT patients who discontinue therapy following simple oral surgical procedures. Critical Summary Assessment The findings suggest that it is not necessary to discontinue OAT for simple oral surgical procedures. Evidence Quality Rating Good

2010 ADA Center for Evidence-Based Dentistry

280. Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures

Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted (...) anticoagulant therapy for simple oral surgical procedures Ralph Rosenblum Jr. DDS, MHA . Overview Systematic Review Conclusion Patients taking oral anticoagulant therapy [OAT] did not experience a higher risk of post-operative bleeding compared to patients not on OAT or OAT patients who discontinue therapy following simple oral surgical procedures. Critical Summary Assessment The findings suggest that it is not necessary to discontinue OAT for simple oral surgical procedures. Evidence Quality Rating Good

2010 ADA Center for Evidence-Based Dentistry